BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17237065)

  • 1. Peak selection from MALDI-TOF mass spectra using ant colony optimization.
    Ressom HW; Varghese RS; Drake SK; Hortin GL; Abdel-Hamid M; Loffredo CA; Goldman R
    Bioinformatics; 2007 Mar; 23(5):619-26. PubMed ID: 17237065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker selection and sample prediction for multi-category disease on MALDI-TOF data.
    Oh JH; Kim YB; Gurnani P; Rosenblatt KP; Gao JX
    Bioinformatics; 2008 Aug; 24(16):1812-8. PubMed ID: 18562269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of mass spectral serum profiles for biomarker selection.
    Ressom HW; Varghese RS; Abdel-Hamid M; Eissa SA; Saha D; Goldman L; Petricoin EF; Conrads TP; Veenstra TD; Loffredo CA; Goldman R
    Bioinformatics; 2005 Nov; 21(21):4039-45. PubMed ID: 16159919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
    Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
    Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma.
    Orvisky E; Drake SK; Martin BM; Abdel-Hamid M; Ressom HW; Varghese RS; An Y; Saha D; Hortin GL; Loffredo CA; Goldman R
    Proteomics; 2006 May; 6(9):2895-902. PubMed ID: 16586431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
    Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
    Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia.
    Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtiö J
    J Proteome Res; 2008 Jun; 7(6):2332-41. PubMed ID: 18452325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative quality-assessment techniques to compare fractionation and depletion methods in SELDI-TOF mass spectrometry experiments.
    Harezlak J; Wang M; Christiani D; Lin X
    Bioinformatics; 2007 Sep; 23(18):2441-8. PubMed ID: 17626063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A strategy for the prior processing of high-resolution mass spectral data obtained from high-dimensional combined fractional diagonal chromatography.
    Valkenborg D; Thomas G; Krols L; Kas K; Burzykowski T
    J Mass Spectrom; 2009 Apr; 44(4):516-29. PubMed ID: 19065607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra.
    Mantini D; Petrucci F; Del Boccio P; Pieragostino D; Di Nicola M; Lugaresi A; Federici G; Sacchetta P; Di Ilio C; Urbani A
    Bioinformatics; 2008 Jan; 24(1):63-70. PubMed ID: 18003646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of early relapse in ovarian cancer using serum proteomic profiling.
    Oh JH; Gao J; Nandi A; Gurnani P; Knowles L; Schorge J
    Genome Inform; 2005; 16(2):195-204. PubMed ID: 16901102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.
    He QY; Zhu R; Lei T; Ng MY; Luk JM; Sham P; Lau GK; Chiu JF
    J Cell Biochem; 2008 Feb; 103(3):740-52. PubMed ID: 17557278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
    Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma.
    Ressom HW; Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R
    J Proteome Res; 2008 Feb; 7(2):603-10. PubMed ID: 18189345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data.
    Park Y; Downing SR; Kim D; Hahn WC; Li C; Kantoff PW; Wei LJ
    Bioinformatics; 2007 Jun; 23(12):1451-8. PubMed ID: 17459967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.